Bevacizumab
Brand names: Lytenava · Active ingredient: Bevacizumab
In short: LYTENAVA is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD).
What is Bevacizumab used for?
LYTENAVA is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD).
Bevacizumab dosage
FOR OPHTHALMIC INTRAVITREAL INJECTION. LYTENAVA must only be administered by a qualified physician.
A 5-micron sterile filter needle (18-gauge x 1½-inch), a 1 mL syringe (with marking to measure 0.05 mL), and a 30-gauge x ½-inch sterile injection needle are needed.
The recommended dose for LYTENAVA is 1.25 mg (0.05 mL of 25 mg/mL) administered by intravitreal injection once monthly (approximately 28 days).
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
The glass vial is for one-time use in one eye only.
Using aseptic technique, the total vial volume of a LYTENAVA vial should be withdrawn through a 5-micron (18-gauge x 1½-inch) sterile filter needle attached to a 1 mL syringe. The filter needle should be discarded after withdrawal of the vial contents and should not be used for the intravitreal injection. The filter needle should be replaced with a sterile 30-gauge x ½-inch needle for the intravitreal injection. The contents should be expelled until the plunger tip is aligned with the line that marks 0.05 mL on the syringe.
Use aseptic technique to carry out the following preparation steps: 1. Prepare for intravitreal injection with the following recommended devices for one-time use (not provided): • 5-micron sterile filter needle (18-gauge x 1½-inch) • 1 mL sterile syringe (with marking to measure 0.05 mL) • sterile injection needle (30-gauge x ½-inch) • alcohol swab 2. Remove the protective plastic cap from the vial. Clean the top of the vial with an alcohol swab. 3. Attach the 5-micron filter needle (18-gauge x 1½-inch) to the syringe by twisting it onto the syringe tip. 4. Push the filter needle into the center of the vial stopper and ensure the tip of the needle remains within the solution to minimize the potential for air bubbles. 5. Withdraw the total volume of LYTENAVA, keeping the vial in an upright position, slightly inclined to ease sufficient withdrawal. 6. Ensure that the plunger rod is drawn sufficiently back when drawing up LYTENAVA in order to completely empty the filter needle. 7. The filter needle should be discarded after withdrawal of the vial contents and must not be used for the intravitreal injection.
8. Attach the 30-gauge x ½-inch sterile injection needle to the syringe by firmly screwing it onto the syringe hub. Carefully remove the needle cap by pulling it straight off. Do not wipe the needle at any time. 9. Hold the syringe with the needle pointing up. If there are any air bubbles, gently tap the syringe with your finger until the bubbles rise to the top. 10. Hold the syringe at eye level and slowly push the plunger rod until the plunger tip is aligned with the line that marks 0.05 mL on the syringe. …
How to take Bevacizumab — instructions & advice from the label
Advise patients that in the days following LYTENAVA administration, patients are at risk of developing endophthalmitis, retinal detachment, and intraocular inflammation. If the eye becomes red, sensitive to light, painful, or develops a change in vision, advise the patient to seek immediate care from an ophthalmologist .
Patients may experience temporary visual disturbances after an intravitreal injection with LYTENAVA and the associated eye examinations . Advise patients not to drive or use machinery until visual function has recovered sufficiently.
LYTENAVAâ„¢ (bevacizumab-vikg) injection
Manufactured by: | LYTENAVA is a trademark of Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. | ©2026 Outlook Therapeutics Inc.
111 S. Wood Ave, Unit #100Iselin, NJ 08830 U.S.U.S. License No.: 2292
Warnings & precautions
Do not take this medicine if: LYTENAVA is contraindicated in patients with ocular or periocular infections.
LYTENAVA is contraindicated in patients with active intraocular inflammation.
LYTENAVA is contraindicated in patients with known hypersensitivity to bevacizumab products or any of the ingredients in LYTENAVA. Hypersensitivity reactions may manifest as severe intraocular inflammation.
Intravitreal injections have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique should always be used when administering LYTENAVA. In addition, patients should be monitored following the injection to permit early treatment should an infection occur .
Increases in intraocular pressure have been noted post-injection (up to 60 minutes) while being treated with LYTENAVA. Monitor intraocular pressure prior to and following intravitreal injection with LYTENAVA and manage appropriately .
Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LYTENAVA clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).
Bevacizumab side effects
The following adverse reactions are discussed in greater detail in other sections of the label:
Hypersensitivity
Endophthalmitis and Retinal Detachments
Increases in Intraocular Pressure
Thromboembolic Events
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in one clinical trial of a drug cannot be directly compared with rates in the clinical trials of the same or another drug and may not reflect the rates observed in practice.
The data described below reflect exposure to LYTENAVA in 601 patients in five clinical trials .
Table 1 shows the most common ocular adverse reactions in patients treated with LYTENAVA compared with ranibizumab 0.5 mg.
Adverse Reactions | LYTENAVA 1.25 mg (N = 601) | Ranibizumab 0.5 mg (N = 345)
Conjunctival hemorrhage | 4% | 3%
Eye pain | 2% | 1%
Vitreous floaters | 2% | 1%
Less common ocular adverse reactions reported in the study eye in <1% of patients treated with LYTENAVA were corneal abrasion, dry eye, eye irritation, and intraocular pressure increased.
About this medicine
Bevacizumab-vikg is a recombinant humanized IgG1 monoclonal antibody specific for human vascular endothelial growth factor (VEGF). Bevacizumab-vikg has a molecular weight of approximately 149 kDa (kilodaltons) and was produced using recombinant CHO cells.
LYTENAVA (bevacizumab-vikg) injection is a sterile, colorless to light brown, opalescent solution for intravitreal use. LYTENAVA does not contain an anti-microbial preservative.
LYTENAVA is supplied in a single-dose vial designed to deliver 0.05 mL of 25 mg/mL (1.25 mg) aqueous solution that also contains dibasic sodium phosphate (0.06 mg), monobasic sodium phosphate (0.29 mg), polysorbate 20 (0.02 mg), trehalose (2.71 mg), and Water for Injection. The pH is 6.
How it works: Bevacizumab is a human vascular endothelial growth factor (VEGF) inhibitor. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells.LYTENAVA binds to all isoforms of VEGF-A, thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 7f9a3014-b3d4-4943-a83a-92a77d8f947c. Read the full official label on DailyMed.